Jason Gary Sagert

This inventor holds 49 USPTO granted patents and 30 published patent applications, plus 2 CIPO patents and 7 EPO patents, primarily in Activatable Antibodies. Top assignees: Cytomx Therapeutics, Inc., University of California, Crispr Therapeutics Ag. Active years: 2013-2025.

USPTO Granted Patents = 49 (Patent Applications = 30)

% Patents Active = 85.7

CIPO Patents = 2 (Patent Applications = 9)

EPO Patents = 7 (Patent Applications = 15)

Average Co-Inventor Count = 5.6

ph-index = 19

Forward Citations = 950(Granted Patents)

Location History:

Santa Barbara, CA (US) (2013 - 2021)
San Mateo, CA (US) (2015 - 2024)
Cambridge, MA (US) (2021 - 2024)

Company Filing History:

43 out of 94

Cytomx Therapeutics, Inc.

patents

7 out of 15,988

University of California

patents

5 out of 86

Crispr Therapeutics Ag

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Activatable Antibodies

Gene-Edited Cells

Cancer Immunotherapy

Bispecific Antibodies

EGFR Binding

PDL1 Antibodies

Matrix Metalloproteinase

Chimeric Antigen Receptors

Natural Killer Cells

Interleukin-6 Receptor

Cleavable Substrates

Immune Cell Therapy

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12502439 - ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF (2025-12-23),

2. 12459999 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2025-11-04),

3. 12344655 - Gene-edited natural killer cells (2025-07-01),

4. 12304968 - T-cells expressing anti-LIV1 chimeric antigen receptor (2025-05-20),

5. 12209120 - Activatable anti-VEGF scFv (2025-01-28),

6. 12146157 - Anti-PTK7 immune cell cancer therapy (2024-11-19),

7. 11926676 - Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such (2024-03-12),

8. 11890354 - Activatable antibodies that bind epidermal growth factor receptor and methods thereof (2024-02-06),

9. 11802158 - Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same (2023-10-31),

10. 11753466 - Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof (2023-09-12),

11. 11591381 - Gene-edited natural killer cells (2023-02-28),

12. 11548944 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2023-01-10),

13. 11548943 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2023-01-10),

14. 11472875 - Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof (2022-10-18),

15. 11459372 - Gene-edited natural killer cells (2022-10-04),

Title: Jason Gary Sagert - Innovative Inventor from San Mateo

Introduction: Jason Gary Sagert is a prolific inventor based in San Mateo, California, known for his groundbreaking contributions to various industries.

Latest Patents: Jason Gary Sagert holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Jason Gary Sagert has worked with top companies to bring his inventions to life, revolutionizing the way we interact with everyday products.

Collaborations: Throughout his career, Jason Gary Sagert has collaborated with leading researchers, engineers, and designers to push the boundaries of innovation and create solutions that make a difference in people's lives.

Conclusion: Jason Gary Sagert's passion for innovation and his relentless drive to create have solidified his position as a respected inventor in the industry, with a legacy that continues to inspire future generations.